Login / Signup
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab.
David Lim
Rhiannon Bandiera
Elizabeth Handsley
Published in:
The Medical journal of Australia (2021)
Keyphrases
</>
ulcerative colitis
high intensity
early onset
drug induced